Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.4M | $55.7M | $85.1M | $98.4M | $154M | $185M | $170M | $179M | $277M |
| Revenue growth | — | 44.8% | 52.8% | 15.6% | 56.9% | 20.1% | -8.1% | 5.1% | 54.8% |
| Operating income | -$44.5M | -$49.8M | -$78.4M | -$153M | -$209M | -$200M | -$227M | -$163M | -$57.1M |
| Operating margin | -115.7% | -89.4% | -92.1% | -155.3% | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Net income | -$42.8M | -$46.4M | -$68.6M | -$146M | -$207M | -$200M | -$225M | -$159M | -$59.5M |
| Net margin | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| EPS (diluted) | -$3.50 | -$3.67 | -$1.01 | -$1.11 | -$1.48 | -$1.40 | -$1.56 | -$1.08 | -$0.39 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.9M | -$32.3M | $205M | -$150M | -$193M | -$184M | -$156M | -$95.2M | -$46.0M |
| Capital expenditures | $2.42M | $6.30M | $11.2M | $18.8M | $61.7M | $16.3M | $10.7M | $3.66M | $2.96M |
| Free cash flow | -$37.3M | -$38.6M | $194M | -$168M | -$254M | -$200M | -$167M | -$98.9M | -$48.9M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $55.0M | $96.6M | $123M | $139M | $90.0M | $65.1M | $47.9M | $70.5M |
| Total assets | — | $333M | $912M | $1.12B | $923M | $857M | $661M | $539M | $513M |
| Total liabilities | — | $29.9M | $341M | $373M | $319M | $393M | $353M | $337M | $288M |
| Long-term debt | — | — | — | — | — | $125M | $131M | $132M | $127M |
| Shareholders' equity | -$225M | -$258M | $571M | $743M | $604M | $464M | $308M | $203M | $219M |
| Retained earnings | — | -$296M | -$365M | -$512M | -$719M | -$919M | -$1.14B | -$1.30B | -$1.36B |
| Shares (wtd avg diluted) | — | 12.8M | 125M | 131M | 140M | 143M | 144M | 147M | 152M |
Every figure is extracted from Adaptive Biotechnologies Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.